Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)

ConditionGiant Cell Arteritis

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age50+

SponsorUniversity of Pennsylvania

About this trial

The research study is being conducted to determine the utility of magnetic resonance imaging (MRI) in identifying inflammation of arteries supplying blood to the head, brain, and eyes. The target population includes patient with suspected giant cell arteritis (GCA; temporal arteritis).

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 50 years or older

First presentation of suspected GCA

New or worsening cranial manifestations within 4 weeks of enrollment concerning for active GCA

Elevated CRP greater than 1.0 mg/dl

Disqualifiers

Absence of cranial symptoms related to GCA (e.g., only large vessel GCA)

Trial population

Participants will be recruited from the ambulatory clinic, emergency department, or inpatient settings.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Magnetic Resonance Imaging (MRI)
Diagnostic test
Combined orbital and cranial vessel wall MRI

Treatment groups

400 Participants

are divided into 3 treatment groups

Group A: Ocular GCA1 intervention

Group B: Non-Ocular GCA1 intervention

Group C: Non-GCA1 intervention

Trial outcomes

Primary outcomes

Vessel Wall Enhancement Score

Enhancement of cranial vessel wall, orbital structures, or other cranial structures. Scores range from 0 to 3; 0 being no inflammation and 3 being more enhancement or inflammation.

Time frame

Up to 12 months